FIGURES AND TABLES

FROM:

Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C

P A Whitehouse, S J Mercer, L A Knight, F Di Nicolantonio, A O'Callaghan and I A Cree on behalf of the Portsmouth Upper GI and Colorectal Cancer Multidisciplinary Teams

Figure 1.

Summary of the heterogeneity of activity in the ATP-TCA to MMC, gemcitabine, and the combination (GeM) in (A) colorectal cancer (n=39), and (B) oesophagogastric cancer (n=21). The IndexSUM is a parameter describing the concentration–inhibition curve for each drug, or combination in a single number. Using the IndexSUM <300 to indicate sensitivity, GeM is clearly more active than either single agent.

Full figure and legend (125K)

Figure 2.

(A) Inhibition–concentration curve in a colorectal tumour sample. (B) By the method of Poch et al. (1995), the observed effect of the combination at each concentration is greater than the expected effect (independent action).

Full figure and legend (57K)

Figure 3.

Schedule studies of gemcitabine in combination with MMC. No schedule dependency has been demonstrated.

Full figure and legend (34K)

Table 1 - Summary of sensitivity data (using an arbitrary threshold of sensitivity defined as a IndexSUM<300 for six concentrations used).

Full table